OnKure Therapeutics, Inc. (OKUR): auditor change — Legacy OnKure posts $35.2M net loss in 9mo; auditor switched to KPMG post-merger

OnKure Therapeutics, Inc.

Net loss of $35.2M for nine months ended Sep 30, 2024, vs $25.9M in prior year.
Cash and equivalents $8.0M as of Sep 30, 2024; accumulated deficit $137.3M.
Ernst & Young dismissed as auditor; KPMG engaged as new independent registered public accounting firm.
Merger with Reneo closed Oct 4, 2024; management expects combined cash to fund operations for at least 12 months.
Convertible notes payable of $6.0M issued in 2024, net of $142k issuance costs.

item 4.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

OnKure Therapeutics, Inc. engaged KPMG LLP as its auditor.

Action: engagement
Auditor: KPMG LLP

Exact text from the filing

On November 7, 2024, the Audit Committee engaged KPMG as the independent registered public accounting firm of the Company.

View on SEC.gov

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

OnKure Therapeutics, Inc. dismissed Ernst & Young LLP as its auditor.

Action: dismissal
Auditor: Ernst & Young LLP
Successor: KPMG LLP

Exact text from the filing

On November 7, 2024, Ernst & Young LLP ("EY") was dismissed as the independent registered public accounting firm of OnKure Therapeutics, Inc. (formerly Reneo Pharmaceuticals, Inc.) (the "Company").

View on SEC.gov

6 auditor changes filed in the last 30 days. Browse all auditor changes →

OnKure Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-123265

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.